Priapism Risk with Daily 5 mg Tadalafil in Men Treated for BPH

Incidence in Randomized Controlled Trials

In randomized controlled trials of PDE5 inhibitors—including tadalafil—conducted for erectile dysfunction or benign prostatic hyperplasia, no cases of priapism were reported despite enrollment of thousands of participants (high‑quality RCT evidence). [1–4]

Pharmacovigilance data show that prolonged erections and priapism are reported only infrequently with all PDE5 inhibitors, and the absolute incidence is extremely low and not precisely quantified (low‑quality observational evidence). [1–4]
The American College of Physicians guideline states that serious adverse events associated with PDE5 inhibitors occurred in < 2 % of patients, with no statistically significant difference compared with placebo (guideline recommendation). [1–4]

In BPH clinical trials, the most common adverse effects were headache, facial flushing, rhinitis, dyspepsia, back pain, and myalgia; none of these are linked to priapism risk (moderate‑quality trial data). [1–4]

Any history of prolonged priapism (> 4 hours) while using a PDE5 inhibitor constitutes an absolute contraindication to tadalafil, regardless of dose, because prior priapism predicts recurrence and potential permanent erectile‑tissue damage (strong recommendation). 5
No dose of tadalafil, including the 5 mg daily formulation, is considered safe for patients with a prior PDE5‑inhibitor‑induced priapism, as the drug’s mechanism still enhances nitric‑oxide‑mediated smooth‑muscle relaxation (strong recommendation). 5
Tadalafil’s long half‑life (~17.5 hours) would prolong any priapism episode, making emergency management more difficult compared with shorter‑acting agents (strong recommendation). 5
Prescribing tadalafil to a patient with documented prior priapism falls below the standard of care and creates significant medicolegal liability, given the risk of recurrent, irreversible priapism requiring surgical intervention (strong recommendation). 5

For older men with BPH who have no history of priapism, daily tadalafil 5 mg carries a negligible risk of priapism and can be prescribed safely (high‑quality trial evidence). [1–4]
Screen all patients for any prior history of prolonged erection or priapism before initiating tadalafil, as a positive history is an absolute contraindication (strong recommendation). 5